Merck and Moderna Unveil Promising Cancer Vaccine Breakthrough

Pharmaceutical companies Merck and Moderna have made significant progress in developing a personalized mRNA cancer vaccine. The breakthrough, announced on August 22, 2026, has shown promising results in reducing the risk of melanoma returning or spreading.

The vaccine is designed to keep melanoma at bay and doctors hope it will work against many types of tumors. While specific details about the treatment's efficacy are not provided, the news marks a major development in cancer research.